Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use

References

• National Cancer Institute. SEER*Explorer: an interactive website for SEER cancer statistics [Internet]; 2020 [cited 2020 April]. Available from: https://seer.cancer.gov/explorer/.
   Google Scholar
• Sveen A, Kopetz S, Lothe RA. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol. 2020;7(1):817–32.
   Google Scholar
• Rankin A, Klempner SJ, Erlich R, et al. Broad detection of alterations predicted to confer lack of benefit from EGFR antibodies or sensitivity to targeted therapy in advanced colorectal cancer. Oncologist. 2016;21(11):1306–1314.
   PubMed Web of Science ®Google Scholar
• Shiu K-K, Andre T, Kim TW, et al. KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer. J Clin Oncol. 2021;39(3_suppl):6–6.
   Web of Science ®Google Scholar
• Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5(1):22.
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626–1634.
   PubMed Web of Science ®Google Scholar
• Baselga J, Rosen N. Determinants of RASistance to anti-epidermal growth factor receptor agents. J Clin Oncol. 2008;26(10):1582–1584.
   PubMed Web of Science ®Google Scholar
• De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19(3):508–515.
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25(22):3230–3237.
   PubMed Web of Science ®Google Scholar
• Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26(3):374–379.
   PubMed Web of Science ®Google Scholar
• Tejpar S, Celik I, Schlichting M, et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol. 2012;30(29):3570–3577.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–1417.
   PubMed Web of Science ®Google Scholar
• McGregor M, Price TJ. Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC. Future Oncol. 2018;14(24):2437–2459.
   PubMed Web of Science ®Google Scholar
• Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2015;51(5):587–594.
   PubMed Web of Science ®Google Scholar
• Kondo T, Matsubara J, Quy PN, et al. Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer. Cancer Sci. 2021;112(1):296–304.
   PubMed Web of Science ®Google Scholar
• Beaubier N, Tell R, Lau D, et al. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. Oncotarget. 2019;10(24):2384–2396.
   PubMedGoogle Scholar
• Gutierrez ME, Price KS, Lanman RB, et al. Genomic profiling for KRAS, NRAS, BRAF, microsatellite instability, and mismatch repair deficiency among patients with metastatic Colon cancer. J Clin Oncol Precision Oncology. 2019;3(3):1–9.
   Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology, colon cancer, version 4.2020. 2020.
   Google Scholar
• Pruneri G, De Braud F, Sapino A, et al. Next-Generation sequencing in clinical practice: is it a cost-saving alternative to a single-gene testing approach? Pharmacoecon Open. 2021;5(2):285–298.
   PubMed Web of Science ®Google Scholar
• Vanderpoel J, Stevens AL, Emond B, et al. Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer. J Med Econ. 2022; 25(1):457–468.
   PubMed Web of Science ®Google Scholar
• Chawla A, Peeples M, Li N, et al. Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers. J Med Econ. 2018; 21(6):543–552.
   PubMed Web of Science ®Google Scholar
• United States Federal Reserve. Consumer price index for all urban consumers: medical care services in U.S. city average, index; 1982. 1984 = 100, Annual, Seasonally Adjusted; 2020 [cited 2020 July 20]. Available from: https://fred.stlouisfed.org/series/CUSR0000SAM2#0.
   Google Scholar
• Beaubier N, Bontrager M, Huether R, et al. Integrated genomic profiling expands clinical options for patients with cancer. Nat Biotechnol. 2019;37(11):1351–1360.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare and Medicaid Services. Total medicare enrollment: part A and part B enrollees, by demographic characteristics, calendar year 2018. 2018. Available from: https://www.cms.gov/files/document/2018-mdcr-enroll-ab-5.pdf.
   Google Scholar
• Berchick ER, Barnett JC, Upton RD. Current population reports, Health Insurance Coverage in the United States: 2018, P60-267(RV) Washington (DC): U.S. Government Printing Office; 2019. Available from: https://www.census.gov/content/dam/Census/library/publications/2019/demo/p60-267.pdf.
   Google Scholar
• U.S. Census Bureau. Main projections series for the United States (2017-2060): projected age groups and sex composition of the population 2017. Available from: https://www.census.gov/data/tables/2017/demo/popproj/2017-summary-tables.html.
   Google Scholar
• Bendell JC, Bekaii-Saab TS, Cohn AL, et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist. 2012;17(12):1486–1495.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.
   PubMed Web of Science ®Google Scholar
• Yaeger R, Chatila WK, Lipsyc MD, et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell. 2018;33(1):125–136.e3.
   PubMed Web of Science ®Google Scholar
• Tempus. Tempus xT (v4) gene panel reports; 2020 [cited 2021 Jan 12]. Available from: https://www.tempus.com/wp-content/uploads/2020/10/xTGene-List_100620-1.pdf.
   Google Scholar
• Tempus. Tempus xT (v4) validation summary: Tempus; 2020 [updated September 28; cited 2021 Jan 12]. Available from: https://www.tempus.com/wp-content/uploads/2020/10/xTv4-Validation_100620.pdf.
   Google Scholar
• Dufraing K, Keppens C, Tack V, et al. Evolution of RAS testing over time: factors influencing mutation rates in metastatic colorectal cancer patients. Colorectal Cancer. 2020;9(1):CRC14.
   PubMed Web of Science ®Google Scholar
• Snowsill T, Coelho H, Huxley N, et al. Molecular testing for lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation. Health Technol Assess. 2017;21(51):1–238.
   Web of Science ®Google Scholar
• Caris. MI Tumor Seek™ technical specifications: Tempus; 2020 [updated June 29; cited 2022 May 13]. Available from: https://www.carismolecularintelligence.com/wp-content/uploads/2018/10/MI-Tumor-Seek-Profile-Menu.pdf.
   Google Scholar
• Genetic Testing Registry (GTR). Caris MI TumorSeek comprehensive genomic profile: performance characteristics; 2022 [updated April 8; cited 2022 May 13]. Available from: https://www.ncbi.nlm.nih.gov/gtr/tests/560898/performance-characteristics/.
   Google Scholar
• Milbury CA, Creeden J, Yip WK, et al. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors. PLOS One. 2022;17(3):e0264138.
   PubMed Web of Science ®Google Scholar
• Fabrizio DA, George TJ, Jr Dunne RF, et al. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. J Gastrointest Oncol. 2018;9(4):610–617.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. Clinical laboratory fee schedule; 2020 [cited 2021 Jan 12]. Available from: https://www.cms.gov/Medicare/Medicare-fee-for-service-Payment/clinicallabfeesched/index.html.
   Google Scholar
• CAQH. Conducting electronic business transactions: why greater harmonization across the industry is needed: CAQH; 2020 [cited 2021 Janu 12]. Available from: https://www.caqh.org/sites/default/files/explorations/index/report/2019-caqh-index.pdf?
   Google Scholar
• Chawla A, Janku F, Wheler JJ, et al. Estimated cost of anticancer therapy directed by comprehensive genomic profiling in a single-center study. J Clin Oncol Precision Oncology. 2018;2:PO.18.00074.
   PubMed Web of Science ®Google Scholar
• Signorovitch J, Zhou Z, Ryan J, et al. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer. J Med Econ. 2019; 22(2):140–150.
   PubMed Web of Science ®Google Scholar
• Yencho S, Austin J, Betka E, et al. Cancer healthcare utilization impact of precision therapeutics: hospitalization/emergency visits. Cancer Sci Res. 2020;3(3):1–3.
   Google Scholar
• Hirshfield KM, Tolkunov D, Zhong H, et al. Clinical actionability of comprehensive genomic profiling for management of rare or refractory cancers. Oncologist. 2016;21(11):1315–1325.
   PubMed Web of Science ®Google Scholar
• Cobain EF, Wu Y-M, Vats P, et al. Assessment of clinical benefit of integrative genomic profiling in advanced solid tumors. JAMA Oncol. 2021;7(4):525–533.
   PubMed Web of Science ®Google Scholar
• Nesline MK, DePietro P, Dy GK, et al. Oncologist uptake of comprehensive genomic profile guided targeted therapy. Oncotarget. 2019;10(45):4616–4629.
   PubMedGoogle Scholar
• National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology, rectal cancer, version 6.2020; 2020.
   Google Scholar